DNMT1 regulates expression of MHC class I in post-mitotic neurons by Gustafsson, Julie Ry et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
DNMT1 regulates expression of MHC class I in post-mitotic neurons
Gustafsson, Julie Ry; Katsioudi, Georgia; Degn, Matilda; Ejlerskov, Patrick; Issazadeh-









Citation for published version (APA):
Gustafsson, J. R., Katsioudi, G., Degn, M., Ejlerskov, P., Issazadeh-Navikas, S., & Kornum, B. R. (2018).
DNMT1 regulates expression of MHC class I in post-mitotic neurons. Molecular Brain, 11(1), 1-16. [36].
https://doi.org/10.1186/s13041-018-0380-9
Download date: 03. Feb. 2020
RESEARCH Open Access
DNMT1 regulates expression of MHC class I
in post-mitotic neurons
Julie Ry Gustafsson1, Georgia Katsioudi1, Matilda Degn1, Patrick Ejlerskov2, Shohreh Issazadeh-Navikas2
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Abstract
Major Histocompability Complex I (MHC-I) molecules present cellularly derived peptides to the adaptive immune
system. Generally MHC-I is not expressed on healthy post-mitotic neurons in the central nervous system, but it is
known to increase upon immune activation such as viral infections and also during neurodegenerative processes.
MHC-I expression is known to be regulated by the DNA methyltransferase DNMT1 in non-neuronal cells. Interestingly
DNMT1 expression is high in neurons despite these being non-dividing. This suggests a role for DNMT1 in neurons
beyond the classical re-methylation of DNA after cell division. We thus investigated whether DNMT1 regulates MHC-I
in post-mitotic neurons. For this we used primary cultures of mouse cerebellar granule neurons (CGNs). Our results
showed that knockdown of DNMT1 in CGNs caused upregulation of some, but not all subtypes of MHC-I genes. This
effect was synergistically enhanced by subsequent IFNγ treatment. Overall MHC-I protein level was not affected by
knockdown of DNMT1 in CGNs. Instead our results show that the relative MHC-I expression levels among the different
MHC subtypes is regulated by DNMT1 activity. In conclusion, we show that while the mouse H2-D1/L alleles are
suppressed in neurons by DNMT1 activity under normal circumstances, the H2-K1 allele is not. This finding is
particularly important in two instances. One: in the context of CNS autoimmunity with epitope presentation by specific
MHC-I subtypes where this allele specific regulation might become important; and two: in amyotropic lateral sclerosis
(ALS) where H2-K but not H2-D protects motor neurons from ALS astrocyte-induced toxicity in a mouse model of ALS.
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Introduction
Involvement of the immune system is a common trait in
several neurodegenerative diseases and autoimmune dis-
eases which affect the central nervous system (CNS) [1, 2],
and the etiology of these neurological disorders is often not
determined. Many autoimmune diseases are associated
with certain Major Histocompability Complex (MHC)
alleles, including type 1 narcolepsy that has a very strong
association with HLA-DQB1*06:02 and are also associated
with certain HLA class I alleles [3, 4]. MHC class I signaling
has also been suggested to play a role in neurodegenerative
disorders such as Parkinson’s disease and Amyotrophic
Lateral Sclerosis (ALS) [5, 6]. Our goal with the current
study was to thus study the regulation of MHC class I
(MHC-I) in neurons.
The CNS was originally considered an immune privileged
organ [7], however this perception is no longer prevalent.
We now know that peripheral T cells can enter the CNS,
both when recruited by chemokines upon viral infection of
neurons [8] and also as routine monitoring where memory
T cells can be reactivated by antigen-presenting dendritic
cells in the perivascular and subarachnoid space [9]. A
range of autoimmune CNS diseases involving neuronal
destruction is likely mediated by CD8+ T cells, as suggested
by the presence of CD8+ T cells in affected brain areas in
Rasmussen’s encephalitis [10], paraneoplastic neuronal
degeneration [11], and Multiple Sclerosis [12] which is
otherwise considered a CD4+ T cell driven disease. CD8+ T
cell mediated neuronal destruction depends however on
activation by interaction with MHC-I molecules, which are
not expressed on healthy post-mitotic neurons under
non-pathological conditions [13, 14]. MHC-I is in contrast
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expressed in neurons at early developmental stages but gets
downregulated in adulthood [15–17]. During development,
MHC-I molecules have been shown to negatively regulate
synaptic density [18], and the establishment of cortical
connections [19]. In adulthood, the same functions seem to
play a role under different pathological conditions. In the
middle cerebral artery occlusion (MCAO) model of stroke,
MHC-I knock out mice (H2-Kb and H2-Db double knock
out) have smaller infarct areas and better behavioral recov-
ery [20]. In contrast, under conditions of axonal injury,
MHC class I molecules seem to play a beneficial role and
have for instance been found to protect specific synaptic
contacts from detachment [21].
MHC-I molecules are readily induced on neurons upon
interferon gamma (IFNγ) treatment [13, 14], and is also reg-
ulated by neuronal activity during development [16, 22, 23].
Several studies have shown that when MHC-I is induced on
neurons, CD8+ T cells can recognize and kill the
MHC-I-expressing neurons subsequently [24–26]. MHC-I
molecules have also been shown to play a role in neurode-
generative disease. A common theme here is that MHC-I
molecules are higher on vulnerable neuronal cell types, such
as dopaminergic neurons (Parkinsons disease) and motor
neurons (ALS). In these cases MHC-I expression seems to
be protective and is downregulated with disease progression
[5, 6]. Thus, insight into the mechanisms keeping MHC-I
expression on neurons in check is of interests for a variety
of CNS diseases.
A missense mutation in the DNA methyltransferase 1
gene (DNMT1) causes the neurodegenerative disease
ADCA-DN (Autosomal dominant cerebellar ataxia,
deafness and narcolepsy), where three neuronal cell types
particularly vulnerable to autoimmunity are lost: the hypo-
cretin neurons (lost in narcolepsy), the cerebellar Purkinje
neurons (lost in paraneoplastic cerebellar neurodegenera-
tion), and neurons of the inner ear (lost in autoimmune
hearing loss) [27], showing that changes in DNMT1 activity
affects post mitotic neurons with devastating consequences.
Our specific aim was thus to investigate whether
DNMT1 activity regulates MHC-I expression on neurons.
We here provide proof-of-principle data using neuroblast-
oma cell lines and next show that the mechanism also ex-
ists in post mitotic neurons. We chose cerebellar granule
neurons (CGNs) as a model, as the neurons are prepared
from postnatal pups and the neurons in culture are
post-mitotic [28, 29]. DNMT1 mRNA have been detected
at high levels at this stage in cerebellum [30], and DNMT1
protein have been detected in CGNs from mice [31].
Results
Inhibitors of DNMT1 increase MHC-I gene expression in
dividing human and mouse neuroblastoma cell lines
To test whether MHC-I genes are regulated by DNMT1
in neuron-like cell lines, we added inhibitors to both
human and mouse neuroblastoma cell lines and analyzed
gene expression of the MHC-I genes. Procainamide
(PCA) is a known inhibitor of DNMT1 [32]. Treatment
with PCA for 72 h, dose-dependently induced significant
HLA-A and HLA-B gene expression in human SK-N-AS
(Fig. 1a and b). Gene expression of HLA-A was increased
1.5 fold by both 1 mM and 2 mM PCA compared to
untreated cells (p = 0.036, and p = 0.014 respectively)
(Fig. 1a). Gene expression of HLA-B was increased 2.9
fold by 1 mM PCA (p = 0.0083) and 5.5 fold by 2 mM
PCA (p < 0.001) (Fig. 1b). Basal relative expression level
of HLA-A was 17.1% while the basal level of HLA-B was
0.03%, compared to endogenous expression levels of
β-Actin (ACTB) and GAPDH. HLA-C was not
detectable in these cells. The basal relative levels of
other relevant genes were: β2M = 30.7%, DNMT1 = 5.0%,
DNMT3a = 2.7%, and DNMT3b = 0.01%.
We also tested whether knocking down DNMT1 or the
other DNA methyltransferases DNMT3a and DNMT3b, in
human SK-N-AS cells would affect expression levels of
HLA-A and HLA-B. We evaluated the gene expression
compared to non-targeting siRNA (baseline, Additional file 1:
Figure S1A-F) for each of the genes of interests HLA-A,
HLA-B, and β2M, as well as of the targeted genes DNMT1,
DNMT3a and DNMT3b, upon treatment for 72 h with
either non-targeting siRNA, siRNA against DNMT1, siRNA
against DNMT3a, or siRNA against DNMT3b (Additional
file 1: Figure S1). Specific downregulation of the targeted
DNMT was obtained for all three DNMTs. DNMT1 gene
expression was decreased by 43% upon treatment with
siRNA against DNMT1 (p= 0.019 versus non-targeting
siRNA) (Additional file 1: Figure S1A). This resulted in a
significant upregulation of HLA-A expression by 50% (p =
0.0061 versus non-targeting siRNA) (Additional file 1:
Figure S1D). We observed a non-significant tendency to-
wards upregulation of HLA-B and β2M as well. DNMT3a
levels was decreased by 32% upon treatment with siRNA
against DNMT3a (p= 0.017 versus non-targeting siRNA)
(Additional file 1: Figure S1B), and DNMT3b levels was
decreased by 48% upon treatment with siRNA against
DNMT3b (p= 0.029 versus non-targeting siRNA) (Add-
itional file 1: Figure S1C). Neither of these changes resulted
in significant effects on HLA-A, HLA-B or β2M, even
though we did see tendencies towards upregulation when
DNMT3b was knocked down.
To validate whether a similar regulation of MHC-I
genes also existed in mouse cells, we evaluated the
expression of H2 genes in mouse N2a neuroblastoma
cell lines upon 72 h of treatment with the inhibitor of
DNMT1 and DNA methylation 5-aza-2-deoxycytidine
(5-aza). The N2a cell line is derived from strain A mice
and thus carries the HLA-I subtypes H2-Kk, H2-Dd, and
H2-Ld. We used 5-aza rather than PCA in the N2a cell
lines, as 5-aza has been used regularly in N2a
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neuroblastoma cell lines [33, 34], and as we experienced
an unintended (and likely compensatory) increase in
DNMT3b gene expression level upon treatment with
PCA (data not shown). H2-K1 and H2-D1/L gene
expression levels were significantly increased by both
5 μM and 80 μM 5-aza compared to no treatment
(H2-K1 increased 8.1 fold by 5 μM (p = 0.018), H2-K1
increased 14.6 fold by 80 μM (p = 0.0044), H2-D1/L
increased 4.0 fold by 5 μM (p = 0.023), and 9.1 fold by
80 μM (p = 0.0037) (Fig. 1c and e). H2-D1 was only
significantly increased by 80 μM to 2.9 fold compared to
untreated (p = 0.021) (Fig. 1d). Basal relative expression
levels of the genes compared to endogenous expression
levels of ACTB and GAPDH were: β2M = 19.0%, H2-K1
= 15.3%, H2-D1 = 8.3%, H2-D1/L = 29.5%. IFNγ was used
as a positive control for HLA/H2 induction in all experi-
ments, and induced all HLA and H2 genes significantly,
except for H2-D1/L which was induced 3.06 fold com-
pared to untreated N2a cells (p = 0.06) (Fig. 1a-e). These
results demonstrate that MHC-I gene expression is
regulated by DNMT1 in both the human SK-N-AS and
the mouse N2a neuroblastoma cell lines.
Knockdown of DNMT1 increase MHC-I gene expression in
post-mitotic mouse CGNs
We next aimed at addressing whether MHC-I gene
expression was also regulated by DNMT1 in
post-mitotic neurons. We used CGNs for this purpose.
We derived the CGNs from Balb/C mice that carry the
HLA-I subtypes H2-Kd, H2-Dd, and H2-Ld. All known
small molecule inhibitors of DNA methyltransferases are
developed for dividing cells [35], and as expected PCA
and 5-aza did not have any significant effect on H2
genes in CGNs (data not shown). Thus we decided to
investigate regulation of H2 genes in CGNs by knocking
down DNMT1, DNMT3a and DNMT3b, one at a time.
We evaluated the gene expression compared to un-
treated CGNs (baseline 1, Fig. 2a-f ) for each of the genes
of interests β2M, H2-K1, H2-D1 and H2-D1/L, as well as
of the targeted genes DNMT1, DNMT3a and DNMT3b,
upon treatment for 72 h with either non-targeting
siRNA, siRNA against DNMT1, siRNA against
DNMT3a, or siRNA against DNMT3b (Fig. 2a-e, bars
from left to right on X-axis). In baseline conditions the
relative expression levels of the different genes differed
markedly in CGNs. When compared to the endogenous
expression of ACTB and GAPDH, expression levels
were: β2M = 25.5%, H2-K1 = undetectable, H2-D1 =
0.37%, H2-D1/L = 35.9%, DNMT1 = 4.9%, DNMT3a =
2.6%, and DNMT3b = 0.05%.The effect of the different
treatments was evaluated by statistical testing against
non-targeting siRNA to exclude unspecific effects of the
transfection procedure. Specific downregulation of the
targeted DNMT was obtained for all three DNMTs.
DNMT1 gene expression was decreased by 60% upon
treatment with siRNA against DNMT1 compared to un-
treated (p < 0.0001 versus non-targeting siRNA) (Fig. 2a),
DNMT3a levels was decreased by 71% upon treatment
with siRNA against DNMT3a (p < 0.0001 versus
non-targeting siRNA) (Fig. 2b), and DNMT3b levels was
decreased by 63% upon treatment with siRNA against
DNMT3b (p < 0.0001 versus non-targeting siRNA) (Fig.
2c), whereas neither DNMT1, DNMT3a, nor DNMT3b
levels were affected significantly by other treatments
Fig. 1 Inhibitors of DNMT1 increase MHC-I gene expression in neuroblastoma cell lines. PCA dose-dependently increased HLA-A gene expression (a)
and HLA-B gene expression (b) in human neuroblastoma cell line SK-N-AS. 5-aza dose-dependently increased the gene expression of H2-K1 (c), H2-D1
(d), and H2-D1/L (e) in mouse neuroblastoma cell line N2a. 72 h treatment with IFNγ (0,2 ng/uL in SK-N-AS and 0,5 ng/uL in N2a) significantly increases
gene expression of HLA-A (a), HLA-B (b), H2-K1 (c) and H2-D1 (d). H2-D1/L gene expression was increased, but not significantly (p = 0.06) (e). Bars
represent mean +/− S.E.M., N = 3. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. untreated in a One-Way ANOVA with Dunnett’s post hoc test
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(Fig. 2a-c). As observed in the neuroblastoma cell lines,
the different genes encoding MHC-I responded differ-
ently to the treatments. The level of β2M was unaffected
by any of the treatments (Fig. 2d). There was no signal
from H2-K1 in any of the samples, suggesting that this
gene is not expressed in post-mitotic CGNs, and that it
cannot be induced by changes in DNMT activity. Signal
from the H2-D1 probe was heavily influenced by
non-targeting siRNA (Fig. 2e). Although treatment with
DNMT1 siRNA did cause a 2-fold increase in H2-D1
gene expression compared to untreated CGNs, this
effect was not significantly different from the H2-D1
expression levels upon treatment with non-targeting
siRNA (Fig. 2e). Finally, treatment with siRNA against
DNMT1 caused a 1.74 fold increase in H2-D1/L com-
pared to untreated CGNs (p < 0.0001) (Fig. 2f ), which
was also significantly different from the effect of
non-targeting siRNA on H2-D1/L (p < 0.0001) (Fig. 2f ).
Knockdown of DNMT3a or DNMT3b did not affect the
expression levels of H2-D1/L showing that the effect is
specific for DNMT1.
Even though Purkinje cells are notoriously difficult to
culture, CGN cultures can contain a small number of
Purkinje cells. We wanted to test the possibility that the
observed changes was caused by large changes in the
small fraction of Purkinje cells. We therefore measured
the level of calbindin, a well known marker of Purkinje
neurons, in our cultures. Calbindin was only borderline
detectable by qPCR, and we did not observe any signifi-
cant differences between the different treatments (data
not shown).
Knockdown of DNMT1 decrease markers of synaptic
function in post-mitotic mouse CGNs
Since MHC-I plays a role in synaptic plasticity
during development [18, 19], and further has been
suggested to also aid in synaptic pruning in the adult
brain [21], we speculated whether the mechanism for
upregulation of H2-D1/L following DNMT1 knock
down, could be linked to changes in synaptic func-
tion in the cultures. To address this we measured
two markers of synaptic function: synaptophysin and
the vesicular glutamate transporter 1 (VGlut1).
Synaptophysin is important for efficient synaptic
vesicle trafficking [36] and for activity-dependent
synapse formation [37], while VGlut1 is involved in
glutamate vesicular release in mature CGNs [38]. In
the experiment, DNMT1 gene expression was de-
creased by 76% upon treatment with siRNA against
DNMT1 compared to non-targeting siRNA (n = 5, p
= 0.0011) (Fig. 3a), while H2-D1/L was increased 1.76
fold compared to non-targeting siRNA treatment of
the CGNs (p = 0.049) (Fig. 3b). In the same experi-
ment, DNMT1 siRNA treatment caused a 89%
downregulation of synaptophysin (p = 0.0022) and
VGlut1 was decreased by 92% (p = 0.0018) (Fig. 3c
Fig. 2 Knockdown of DNMT1 increases MHC-I gene expression in post-mitotic mouse CGNs. Shown is the fold change in gene expression of DNMT1 (a),
DNMT3a (b), DNMT3b (c), β2M (d), H2-D1 (e), and H2-D1/L (f) following 72 h siRNA treatment of CGN cultures. Baseline indicate gene expression level in
untreated CGNs. Bars represent mean +/− S.E.M., N= 8 from three independent experiments. Stars illustrate effects that are significantly different from
untreated CGNs, unless otherwise indicated. * p< 0.05, *** p< 0.001, multiplicity corrected p-values in a Two-Way ANOVA with Dunnett’s post hoc test
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and d). These results show that knock down of
DNMT1 significantly affects expression of synaptic
markers, while knock-down of DNMT3a or
DNMT3b has no effect.
Blockade of DNMT1 acts in synergy with IFNγ to induce
MHC-I gene expression
IFNγ is a known inducer of MHC-I expression on neu-
rons. It has been reported that IFNγ and the demethylat-
ing agent zebularine work in synergy to increase
expression of indoleamine 2,3-dioxygenase 1 (IDO1) -an-
other gene known to be induced by IFNγ [39]. We there-
fore next examined whether the same synergy existed for
MHC-I in neurons. To investigate a possible synergetic ef-
fect in N2a cells, we lowered the dose of 5-aza to 0.5 μM,
and the time of IFNγ treatment to 24 h to avoid ceiling ef-
fects that could occur with the 72 h treatment. Due to this
short timeframe of IFNγ treatment, we did not observe
any induction of H2 genes with IFNγ alone (Fig. 4a-c), as
otherwise observed when cells were treated for 72 h (Fig.
1c-e). The low dose of 5-aza alone significantly induced
H2-D1/L (p = 0.0007) (Fig. 4c), whereas neither H2-K1 nor
H2-D1 were increased upon treatment with 5-aza alone
(Fig. 4a-b). When IFNγ and 5-aza were combined, H2-K1
gene expression was increased by 2 fold compared to un-
treated (p = 0.0007), and this increase was significantly dif-
ferent from both IFNγ alone (p = 0.0003) and 5-aza alone
(p = 0.0023) (Fig. 4a). H2-D1 was not induced significantly
by the combined treatment with IFNγ and 5-aza (Fig. 4b).
Finally, the combined treatment with IFNγ and 5-aza in-
creased H2-D1/L 3.54 fold change compared to untreated
(p = 0.001), which was significantly different compared to
untreated (p = 0.0007), from the 2.48 fold induction ob-
served upon treatment with 5-aza alone (p = 0.038), as
well as from IFNγ treatment alone (p = 0.001) (Fig. 4c).
Taken together these results revealed that blockade of
Fig. 3 Knockdown of DNMT1 decrease markers of synaptic function in post-mitotic mouse CGNs. Shown is the fold change in gene expression of
DNMT1 (a), H2-D1/L (b), synaptophysin (c) and VGlut1 (d) following 72 h siRNA treatment of CGN cultures. Baseline indicate gene expression level
in CGNs treated with non-targeting siRNA. Bars represent mean +/− S.E.M., N = 5 from two independent experiments. Stars illustrate effects that
are significantly different from non-targeting siRNA group. * p < 0.05, ** p < 0.01, multiplicity corrected p-values in a One-Way ANOVA with
Dunnett’s post hoc test
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DNA methyltransfer acts in synergy with IFNγ to induce
expression of some but not all H2 alleles in neurons.
We next addressed synergy between IFNγ treatment and
knockdown of DNMT1 in CGNs. We chose to focus on
DNMT1, as knockdown of DNMT1, rather than DNMT3a
or DNMT3b, caused an increase in H2-D1/L. IFNγ treat-
ment was used as positive control for H2 gene induction in
CGNs and treatment with 0.005 ng/μl IFNγ for 72 h signifi-
cantly increased H2-D1 and H2-D1/L gene expression (Fig.
4d-g). Importantly, IFNγ did not increase H2-K1 gene
expression to detectable levels. We tested two different
treatment combinations and timings. Either IFNγ was
added simultaneously with the siRNA against DNMT1 (Fig.
4d-e), or IFNγ was added for 72 h following treatment with
siRNA against DNMT1 (Fig. 4f-g). When IFNγ was added
simultaneous with the siRNA against DNMT1, H2-D1 (Fig.
4d) and H2-D1/L (Fig. 4e) were induced to the same extent,
as when IFNγ was added in combination with
non-targeting siRNA, indicating no synergy. This was in
contrast to the treatment where IFNγ was added consecu-
tive to siRNA against DNMT1. In this case H2-D1/L was
induced 10.78 fold compared to untreated, which was sig-
nificantly different from the 8.05 fold induction obtained
upon treatment with non-targeting siRNA and then IFNγ
(p = 0.0067) (Fig. 4g), suggesting synergy between knock-
down of DNMT1 and consecutive treatment with IFNγ.
Knockdown of DNMT1 does not increase total MHC-I
protein expression in post-mitotic mouse CGNs
We next examined protein expression of MHC-I protein
upon knockdown of DNMT1 in CGNs by immunofluor-
escence (Figs. 5, 6 and 7) and flow cytometry (Fig. 7). As
Fig. 4 Blockade of DNMT1 acts in synergy with IFNγ to induce MHC-I gene expression. Panel A-C show the effect of combined treatment
of N2a cells with IFNγ and 5-aza. Fold change in gene expression of H2-K1 (a), H2-D1 (b), and H2-D1/L (c) relative to untreated N2a cells.
Bars represent mean +/− S.E.M., N = 3. Panel D-E show the effect of simultaneous treatment of CGNs with IFNγ and siRNA against DNMT1
or non-targeting (NT) control siRNA. Fold change in gene expression of H2-D1 (d), and H2-D1/L (e) relative to untreated CGNs. Bars
represent mean +/− S.E.M., N = 6 from two independent experiments. Panel F-G show the effect of treatment of CGNs with siRNA against
DNMT1 for 72 h, followed by treatment with IFNγ for the next 72 h. Fold change in gene expression of H2-D1 (f), and H2-D1/L (g)
relative to untreated CGNs. Bars represent mean +/− S.E.M., N = 3. Baselines indicate gene expression level in CGNs treated with non-
targeting (NT) siRNA. Stars in A-C illustrate effects that are significantly different from untreated CGNs, and stars in D-G illustrate effects
that are significantly different from CGNs treated with non-targeting siRNA, unless otherwise indicated. * p < 0.05, ** p < 0.01, *** p < 0.001,
multiplicity corrected p-values in a One-Way ANOVA with Dunnett’s post hoc test
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expected, MHC-I protein was undetectable by immuno-
fluorescence in untreated CGNs (Fig. 5a) and in CGNs
treated with non-targeting siRNA for 72 h (Fig. 5c), but
clearly visible on neurons upon treatment with 0.005 ng/
μl IFNγ for 72 h (Fig. 5b). As H2-K1 gene expression
was not induced to detectable levels upon IFNγ treat-
ment, the detected MHC-I protein are of the subtypes
H2-D1 and/or H2-L. In our experimental group, treat-
ment of CGNs with siRNA against DNMT1 for 72 h did
not induce MHC-I protein on the neurons (Fig. 5d).
We then addressed whether the sequential treatment
of CGNs with siRNA against for DNMT1 and then IFNγ,
caused a synergistically effect on MHC-I protein levels
as detected by immunofluorescence, as was the case for
gene expression. We observed a clear MHC-I protein
signal on the neurons treated with IFNγ (Fig. 6a), as well
as for CGNs treated with non-targeting siRNA for 72 h
plus additional 72 h treatment with IFNγ (Fig. 6b), but
the data did not show any additional MHC-I protein
upon treatment with siRNA against DNMT1 for 72 h
plus additional 72 h treatment with IFNγ (Fig. 6c). These
results indicate that the synergestic effect we observed
on gene expression level, does not translate into overall
MHC-I protein levels, but rather shifts the balance be-
tween expressed MHC-I subtypes.
Transfection efficiency is not always complete in
post-mitotic cells and can vary between the individual cells
within the culture, and we therefore next aimed at investi-
gating MHC-I protein expression by immunofluorescence
on neurons that had taken up high amount of the siRNAs
against DNMT1. We therefore transfected CGNs with a mix
of the previously used SMARTpool against DNMT1 and a
Cy3-labelled single siRNA against DNMT1, and performed
immunofluorescence for MHC-I and β-III-tubulin in conju-
gation with detection of the Cy3 signal from the siRNA mix-
ture (Fig. 7). Only 3:7 siRNA molecules were Cy3-labelled to
ensure that only cells that had taken up a significant amount
of siRNA were visibly labelled. This approach also allowed
us to use the original SMART pool in combination with the
Cy3-labelled siRNA to secure consistency. Using this
Fig. 5 Knockdown of DNMT1 does not increase MHC-I protein on neurons detected by immunofluorescence. DNMT1 (green), MHC-I/H2 (red),
and β-III-tubulin (pink) were detected by immunofluorescence performed on untreated CGNs (a), CGNs treated with IFNγ (b), CGNs treated with
non-targeting siRNA (c), and CGNs treated with siRNA targeting DNMT1 (d). Scale bar, 10 μm
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procedure, the Cy3-siRNA was indeed detectable on neu-
rons (arrow), but the neurons positive for Cy3-siRNA did
not display MHC-I protein (Fig. 7c), confirming our results.
Untreated CGNs expressed no MHC-I protein (Fig. 7a),
whereas 72 h treatment with 0.005 ng/μl IFNγ induced
MHC-I protein on the neurons (Fig. 7b).
We supplemented the immunofluorescence with flow
cytometry studies, to be able to examine all neurons in the
culture in a systematic way (Fig. 8). We gated the neurons
by size (Fig. 8a), and viability (Fig. 8b), and then analyzed
the β-III-tubulin-positive population (Fig. 7c) for extracel-
lular MHC-I protein expression (Fig. 8d). Histogram of
MHC-I signal shows overlay of untreated CGNs (purple),
CGNs treated with non-targeting siRNA (green), CGNs
treated with siRNA against DNMT1 (red) and CGNs
treated with 0.005 ng/μl IFNγ for 72 h (blue) (Fig. 8d).
IFNγ treatment induced a MHC-I + population of neurons
(49%) with a median fluorescence intensity of 360,
whereas treatment of CGNs with siRNA against DNMT1
did not induce extracellular MHC-I on the neurons (Fig.
8d) confirming our immunofluorescence data. We next
addressed whether synergy between knockdown of
DNMT1 and IFNγ existed on the MHC-I protein level.
Histograms of MHC-I signal in Fig. 8e-f show overlay of
CGNs treated with non-targeting siRNA and IFNγ (light
green), and CGNs treated with siRNA against DNMT1
and IFNγ (pink), and Fig. 8e shows the results from the
cells receiving siRNA and IFNγ simultaneously (like Fig.
4d-e), whereas Fig. 8f shows the results from the cells re-
ceiving IFNγ after the siRNA (like Fig. 4f-g and Fig. 6).
The percentage of neurons displaying MHC-I signal, as
well as the median fluorescence intensity of the PE-
MHC-I signal, were in both instances comparable between
the cells receiving non-targeting siRNA and IFNγ, and the
cells receiving siRNA against DNMT1 and IFNγ, indicat-
ing no synergy with regard to total MHC-I protein level.
Discussion
In contrast to other nucleated cells, most post-mitotic
neurons do not express MHC-I under non-pathological
Fig. 6 Sequential treatment with IFNγ and siRNA against DNMT1 does not act synergistically to further increase H2 protein on neurons detected
by immunofluorescence. H2 (red), and β-III-tubulin (pink) were detected by immunofluorescence performed on CGNs treated with IFNγ (a), CGNs
treated with non-targeting siRNA and IFNγ (b), and CGNs treated with siRNA targeting DNMT1 and IFNγ (c). Scale bar, 20 μm
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conditions [13, 14]. However, during several pathological
conditions MHC-I expression can be induced in neurons
where they are believed to play an active role in the
disease process. This is the case for both autoimmune
diseases, where neurons can be killed by CD8+ T cells
[24–26], and for neurodegenerative disorders [5, 6].
Knowledge on the molecular mechanisms regulating
neuronal MHC-I might thus be of relevance in a range
of CNS diseases. We chose to address whether MHC-I
expression on neurons is regulated by DNMT1. DNMT1
is traditionally thought of as the maintenance DNA
methyltransferase during cell division, but today we
know that DNMT1 mRNA and protein is expressed in
post-mitotic neurons [30, 31], suggesting a more com-
plex role. It was also previously believed that methyla-
tion patterns were stable in post-mitotic neurons, but it
is now clear that active demethylation is an ongoing
process that in neurons is tightly regulated by multiple
enzymes including the ten eleven translocation (TET)
enzyme TET1 [40–42], and Gadd45b (growth arrest and
DNA-damage-inducible 45β) which is induced upon
neuronal stimulation [43].
MHC-I expression is controlled by methylation in
tumour cell lines and human PBMCs [44, 45]. We here
show that this is also the case in neuron-like cell cul-
tures, by showing that two inhibitors of DNA methyla-
tion (PCA and 5-aza) increased the expression of genes
encoding MHC-I in human and mouse neuroblastoma
cell lines. This effect was observed upon 72 h of incuba-
tion with the compounds, and, as we assume that the
cells have divided in this timespan, this effect most likely
is dependent on the passive demethylation process of
dividing cells.
Importantly, we next examined non-dividing
post-mitotic CGNs. Here we show that a decrease in
DNMT1 specifically causes an increase in H2-D1/L gene
expression, while H2-K1 gene expression was still un-
detectable after DNMT1 knockdown. Importantly,
knockdown of DNMT3a and DNMT3b did not change
H2 levels. This suggests that DNMT1 does indeed have
a more complex role in post-mitotic neurons than
merely being the maintenance DNA methyltransferase.
The increase in MHC-I mRNA expression we ob-
served was not sufficient to cause an upregulation of
MHC-I protein on the surface. For MHC-I protein to be
expressed on the surface, the MHC-I chain needs to
form a stable complex with β2M [46]. β2M baseline
expression was high in CGNs and did not change with
DNMT1 knockdown, we therefore suspect that β2M is
not the rate limiting step for MHC-I surface expression.
Instead additional stimulation is likely needed for
MHC-I to be expressed on the surface. It has for
example been shown that TAP1 and TAP2 expression is
needed for surface expression of MHC-I [47, 48]. The
Fig. 7 CGNs with high uptake of siRNA against DNMT1 do not express MHC-I protein. MHC-I/H2 (green), Cy3-labeled siRNA against DNMT1 (red),
and β-III-tubulin (pink) were detected by immunofluorescence performed on untreated CGNs (a), CGNs treated with IFNγ (b), and CGNs treated
with Cy3-labeled siRNA targeting DNMT1 (c). Arrow indicates colocalizing Cy3-labeled siRNA targeting DNMT1 and β-III-tubulin (neuron with high
uptake of siRNA targeting DNMT1). Scale bar, 10 μm
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relevance of additional factors has been suggested before
in a study of cultured rat hippocampal neurons [49].
The authors showed that 40% of untreated neurons
expressed MHC-I transcripts, but only 10% of the neu-
rons expressed β2M mRNA, and none expressed TAP1
and TAP2 mRNA [49]. Interestingly in the same culture
system, MHC-I was upregulated not only by IFNγ but
also in neurons that had been electrically silenced by
treatment with tetrodotoxin (TTX) [14]. Upregulation of
the entire machinery for MHC-I expression, has also
been shown to occur with aging [50].
We suggest, that by knocking down DNMT1 we create
a situation where H2-D1 and H2-L, but not H2-K1
becomes more accessible for the translational machinery.
This will increase the baseline transcription of the gene
slightly, as we see in our data. The effect is however
small and confined to the mRNA level. For MHC class I
protein to be expressed more factors such as β2M, TAP1
and TAP2 are needed. Changes in DNMT1 levels thus
only affects which H2-genes are expressed but it does
not affect the total rate of protein expression.
If what we suggest is true, and lowering DNMT1 levels
indeed causes the H2-D1/L loci to become more access-
ible, then we should be able to predict that any stimulus
that induces MHC class I protein expression would
induce even more H2-D1/L expression in cells with
lowered DNMT1. This was indeed the case. We first
confirmed that MHC-I protein on the surface of neurons
can be induced by IFNγ alone as previously reported
[13, 14], and in addition we showed that in CGNs, IFNγ
treatment only induce H2-D1 and H2-D1/L gene expres-
sion and not H2-K1 gene expression. When stimulating
the CGNs with IFNγ after DNMT1 knockdown, H2-D1/
L expression was increased by 10.78 fold compared to
untreated CGNs, in contrast to 8.05 fold in CGNs
treated with non-targeting siRNA. The same synergistic
effect was observed in N2a neuroblastoma cell line,
where combined treatment with IFNγ and 5-aza led to
higher gene induction of H2-D1/L gene expression than
the treatment with either one individually. In contrast to
CGNs, H2-K1 was also induced to a higher extent by
IFNγ in N2a cells following 5-aza treatment. Synergy
Fig. 8 Knockdown of DNMT1 does not increase total MHC-I protein level on neurons detected by flow cytometry. CGN cultures were harvested
and processed for flow cytometry, and analyzed the same day. Gating strategy is shown in A-C; a population experimentally determined to
contain neurons were gated based on size (a), and from this population we proceeded with the live cells (b), from which the β-III-tubulin positive
cells (neurons) were gated for further studies (c). D-F show MHC-I histograms for experimental groups gated on the neuronal population.
Whereas treatment with IFNγ (blue) caused MHC-I expression on neurons, no MHC-I positive neurons were detected in untreated CGNs (purple),
CGNs treated with non-targeting siRNA (green), or in CGNs treated with siRNA against DNMT1 (red) (d). Histograms of MHC-I signal in Fig. 8E-F
show overlay of CGNs treated with non-targeting siRNA and IFNγ (light green), and CGNs treated with siRNA against DNMT1 and IFNγ (pink), and
Fig. 8E shows the results from the cells receiving siRNA and IFNγ simultaneously, whereas Fig. 8F shows the results from the cells receiving IFNγ
after the siRNA
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between changes in methylation and IFNγ signaling has
been shown before, in a previous study showing that
IFNγ and the demethylating agent zebularine acted syn-
ergistically to increase the gene expression of IDO1 [39].
Non-targeting siRNA across several experiments con-
sistently induced H2-D1 gene expression or interfered
with its detection for unknown reasons, and it was thus
not possible to distinguish if the H2-D1 induction upon
knockdown of DNMT1 was due to lower levels of
DNMT1, or just the mere presence of a siRNA. How-
ever, the same effect was not observed upon introduc-
tion of siRNA against DNMT3a or DNMT3b, suggesting
that H2-D1 does indeed increase upon DNMT1 knock-
down, and that the signal with non-targeting siRNA was
due to a technical problem with the probes. The probe
detecting both H2-D1 and H2-L (H2-D1/L collectively)
was not influenced by non-targeting siRNA supporting
this idea. With current available probes we cannot dis-
tinguish the signals from H2-D1 and H2-L.
Our results consistently show that knockdown of
DNMT1 does not cause an increase of total MHC-I pro-
tein in neurons, not even in the neurons displaying the
highest uptake of siRNA against DNMT1. Two different
antibodies and techniques were used, strengthening the
credibility of the result. For flow cytometry studies we
investigated surface MHC-I, and the possibility that intra-
cellular MHC-I protein was increased without being
translocated to the cell surface thus exists, however in that
case we would have expected to observe an intracellular
MHC-I signal in immunofluorescence. Another issue is
that the antibodies used for immunofluorescence and flow
cytometry are not subtype-specific antibodies, but rather
were chosen based on their previously reported perform-
ance in immunofluorescence and flow cytometry [23, 51].
It would be interesting to investigate MHC-I protein
using subtype-specific antibodies, but we were not able
to obtain a sufficient signal-to-noise ration with the cur-
rently available subtype-specific MHC-I antibodies.
Our data suggests that DNMT1, when present in neu-
rons, can inhibit expression of the H2-D1/L loci.
Whether this is through a direct effect on methylation
status of the H2-D1 or H2-L loci, or through some other
mechanism, is still unknown. The mechanism could also
be indirect through changes in the transcriptional ma-
chinery induced by the lack of DNMT1 activity. Interest-
ingly, we observe that this effect of DNMT1 does not
affect all H2 loci to an equal extend. Since we at the
same time did not observe any changes in total surface
expression of MHC-I protein, this suggests that it might
instead shift the balance of available MHC-I protein
from one subtype to another. This could be highly im-
portant in the context of autoimmunity, where epitope
presentation to T-cells depend on the MHC-I subtype.
The phenomenon of differential response of the different
MHC-I subtypes have been reported before in peripheral
blood leukocytes, colon mucosa, and larynx mucosa,
with some MHC-I subtypes having a lower constitutive
expression and being more inducible [52, 53]. This could
also play an important role in the development of neuro-
degenerative diseases such as ALS. It has been shown in
a mouse model of ALS, that increasing MHC class I ex-
pression on motor neurons protects the neurons against
astrocyte toxicity [6]. The result was that the mice sur-
vived longer and had a better motor performance. Inter-
estingly, this effect was only seen with H2-K and not
H2-D. This could perhaps be attributed to the fact that
H2-D1 is inhibited by the presence of DNMT1 in ma-
ture motor neurons while H2-K is not.
DNMT1 have been studied in post-mitotic neurons by
others. DNMT1 has for example been found to colocal-
ize with GAD67-positive GABAergic neurons in many
parts of the brain [54]. Curiously, Fan et al. found no ef-
fect of postnatal brain-specific knockdown of DNMT1,
neither on global methylation levels nor on neuronal
long-term survival [31]. The simultaneous gene deletion
of DNMT1 and DNMT3a however, affected synaptic
function, decreased learning and memory formation,
and caused upregulation of MHC-I and STAT1 gene ex-
pression in adult mouse hippocampus [55]. It might
seem contradictory that post-mitotic cells would depend
on continuous methylation, however with the discovery
of an oxidized variant of 5mC, the
5-hydroxymethylcytosine (5hmC), which was discovered
simultaneously in mouse ESCs [42] and in adult mouse
cerebellar Purkinje cells [56], the concept of active de-
methylation arose. Methylated DNA can be demethy-
lated without cell division, when 5hmC is converted to
5C through a series of events involving the TET en-
zymes and base excision repair pathways [40, 42]. Active
demethylation is stimulated by neuronal activity acting
through TET1 and Gadd45b [40–43]. For active demeth-
ylation to occur, and thus for the neurons to depend on
re-methylation by DNMT1, it might be a prerequisite
that the neurons have formed an active network. CGNs
are glutamatergic but receive mostly inhibitory inputs
from GABA and glycine containing synapses. This can-
not be reproduced in vitro, and this might be an import-
ant limitation in our study. It is also possible that such
inherent properties of the neuronal cultures vary from
one preparation of CGNs to another. In light of this, it
would be interesting to study knockdown of DNMT1 in
other in vitro models, such as organotypic slice cultures,
or in combination with induction of active
demethylation. We do detect synaptic markers in our
CGN cultures, and interestingly observe a strong effect
of DNMT1 downregulation on these synaptic markers.
This is particularly interesting as MHC-I are known to
be involved in synaptic plasticity. It is tempting to
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speculate that lack of DNMT1 causes an upregulation of
MHC-I, which in turn causes elimination of synapses in
the CGN culture. The MHC-I surface protein would be
removed in this process explaining why we do not see it.
However, from our present data we can not say anything
about the direction of the correlation between increased
MHC-I expression and lower expression of synaptic
markers. It could also be that DNMT1 plays an import-
ant role in controlling the transcriptional processes
related to synapse maintenance, and that the
upregulation of MHC-I is secondary to this effect. DNA
methylation status has indeed been show to control
transcription-dependent regulation of glutamatergic syn-
aptic homeostasis [57].
In conclusion we have shown that MHC-I gene
expression is regulated by DNMT1 in human and mouse
neuroblastoma cell lines, and that the gene expression of
some but not all H2 subtypes is upregulated in
post-mitotic CGNs upon knockdown of DNMT1. We
moreover show that IFNγ can act in synergy with these
treatments to further increase H2-D1/L gene expression.
Importantly, this effect differs between H2 subtypes.
Methods
SK-N-AS cell culturing and addition of procainamide and
IFNγ
The human neuroblastoma cell line SK-N-AS was ob-
tained from ATCC. SK-N-AS cells were cultured in a
50/50 mixture of Ham’s F-12 media (Gibco, Life Sci-
ences), and Iscove’s Modified Dulbecco’s Medium
(IMDM) (Biowest, Nuaillé, France), supplemented with
10% Fetal calf serum (FCS) (Sigma-Aldrich, St. Louis,
MO, USA), and 0.5% penicillin-streptomycin (P/S)
(Lonza Ltd., Basel, Switzerland). SK-N-AS cells were
seeded at a density of 3 × 10^4 cells/ml at day 1 in Ham’s
F-12/IMDM containing 10% FCS and 0.5% P/S, then on
day 2 media was changed to Ham’s F-12/IMDM contain-
ing 2% FCS and procainamide (PCA) in the dose range
0.1–2 mM or 0.02 ng/μl IFNγ was added to the cells. At
day 5 the cells were harvested for RNA extraction.
siRNA treatment of SK-N-AS cells
SK-N-AS cells were seeded at a density of 75 × 10^4 cells/
ml at day 1 in Ham’s F-12/IMDM containing 10% FCS
and 0.5% P/S. On day 2 media was changed to Ham’s
F-12/IMDM without FCS and P/S containing instead
15 nM siRNA and Lipofectamine 2000 (Life Technolo-
gies). The siRNAs used were Ambion™ Silencer™ Select
siRNA against human DNMT1 (s4215), DNMT3a
(s200426) and DNMT3b (s4221). After 5 h of transfection,
the media was changed to Ham’s F-12/IMDM containing
10% FCS and 0.5% P/S and the cells were incubated for
72 h at 37 °C before harvest and RNA extraction.
N2a cell culturing and addition of 5-aza-2-deoxycytidine
and IFNγ
The murine neuroblastoma cell line N2a was obtained
from ATCC. Undifferentiated N2a cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) high
glucose (Biowest, Nuaillé, France), supplemented with
10% Fetal calf serum (FCS) (Sigma-Aldrich, St. Louis,
MO, USA), and 0.5% penicillin-streptomycin (Lonza
Ltd., Basel, Switzerland). N2a cells were seeded at a
density of 4.5 × 10^4 cells/ml at day 1 and 0.5 ng/μl
IFNγ was added on day 2. 5-aza-2-deoxycytidine (5-aza)
was added on day 2, 3, and 4 in the doses 5 μM and
80 μM, and at day 5 the cells were harvested for RNA
purification. The 5-aza treatment was renewed every
24 h, due to the short half-life of this compound. When
addressing possible synergy between 5-aza treatment
and IFNγ treatment, the same protocol for 5-aza treat-
ment was followed, but with the addition of 0.05 ng/μl
IFNγ at day 4 and with a lower concentration of 5-aza
(0.5 μM).
Preparation and culturing of primary cultures of
cerebellar granular neurons
Primary CGN cultures were prepared from 7 to 9 BALB/
cJBomTac (Taconic, Denmark) pups at postnatal day six,
essentially as described by Schousbo et al. [58]. Cerebel-
lum was isolated from a maximum of two pups at a time,
the meninges removed on ice in a dissection buffer
containing Krebs-Ringer buffer (Substrate-department,
Faculty of Health Science, University of Copenhagen),
Bovine Serum Albumin (BSA) (Sigma-Aldrich, St. Louis,
MO, USA), MgSO4 (RegionH Apoteket), and HEPES buf-
fer (Gibco, Life Sciences), and the remaining tissue was
mechanically and enzymatically homogenized by chopping
and trypsination. Cells were then washed in a buffer con-
taining trypsin inhibitor and DNase I (Sigma-Aldrich, St.
Louis, MO, USA), centrifuged briefly at 100 rpm to stratify
cells, and the uppermost layers were transferred to
Krebs-Ringer buffer supplemented with BSA (Sigma-Al-
drich, St. Louis, MO, USA), MgSO4 (RegionH Apoteket),
HEPES (Gibco, Life Sciences), CaCl2 (RegionH Apoteket).
Upon centrifugation for 10 min. at 700 rpm, the pelleted
cells were resuspended in NBM-A (Gibco, Life Sciences)
supplemented with B27 (Gibco, Life Sciences), BSA (Sig-
ma-Aldrich, St. Louis, MO, USA), Glutamax (Gibco, Life
Sciences), and HEPES (Gibco, Life Sciences). Cells were
seeded at a density of 4 × 10^5 cells/ml in 24-well plates
coated with poly-D-lysine (Sigma-Aldrich, St. Louis, MO,
USA), and incubated at 37 °C, 5% CO2. 24 h after seeding
of cells, cytosine β-D-arabinofuranoside hydrochloride
(Ara-C) (Sigma-Aldrich, St. Louis, MO, USA) was added
to the media to a final concentration of 10 μM to inhibit
the growth of glial cells.
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siRNA for primary cultures of cerebellar granular neurons
The siRNAs against mouse DNMT1, DNMT3a and
DNMT3b were bought as a pool of four siRNAs target-
ing the same gene in different sites, called SMARTpool,
from the Accell range by Dharmacon™, part of GE
Healthcare, Little Chalfont, Buckinghamshire, United
Kingdom (See Additional file 1: Table S1). Negative con-
trol siRNA, “Accell Non-targeting #1” was designed,
modified and microarray-confirmed by Dharmacon™ to
have minimal targeting of known genes in mouse cells.
The siRNAs were diluted in the supplied 5XsiRNA buf-
fer diluted in RNase-free water, according to the manu-
facturer’s instructions, aliquoted and stored at − 20 °C.
Addition of IFNγ and siRNA to primary cultures of
cerebellar granular neurons
On the day of siRNA transfection the normal growth
media of CGNs was exchanged with preheated and
CO2-equilibrated NBM-A media supplemented with
B27, Glutamax and HEPES containing 10 μM Ara-C and
1 μM siRNA, but excluding BSA. Transfection efficiency
was assessed using a Cy3-labelled non-targeting siRNA
(Additional file 1: Figure S1). For studies of the effect of
siRNA on H2 and DNMT genes (Figs. 3 and 4), the effect
of siRNA on MHC-I protein by immunofluorescence
(Figs. 5 and 7), and the effect of siRNA on H2 protein
by flow cytometry (Fig. 8), CGNs were treated with
1 μM siRNA SMARTpool or non-targeting siRNA con-
trol for 72 h prior to harvesting or fixation for further
processing. For detection of the neurons receiving the
SMARTpool against DNMT1 by immunofluorescence
(Fig. 7), the SMARTpool against DNMT1 was mixed 7:3
with a custom-made Cy3-labelled siRNA against
DNMT1, and the mix was then added to cultures in
equimolar amount with regards to the SMARTpool
against DNMT1 as was used in previous experiments. In
these experiments, treatment with 0.005 ng/μl IFNγ for
the same 72 h prior to processesing was used as a posi-
tive control for H2 induction. When testing synergy be-
tween DNMT1 knockdown and IFNγ treatment, two
different protocols were tested. Either 0.005 ng/μl IFNγ
was added on the same day as the siRNAs, followed by
RNA extraction 72 h later (Fig. 4d-e). Alternatively cells
were first subjected to 72 h of siRNA treatment, then
media was exchanged to normal growth media including
10 μM Ara-C and BSA, and 0.05 ng/μl IFNγ was added
to the cells, which were then incubated for another 72 h
before harvest for RNA extraction (Fig. 4f-g) or fixation
for immunofluorescence (Fig. 6).
Quantification of gene expression
Cells were harvested in RLT buffer on ice, and RNA was
purified using RNeasy® Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instruction
for harvesting animal cells. The quality and concentra-
tion of the purified RNA was determined by measuring
optical density (OD, 260/280) on a NanoDrop 2000c
Spectrophotometer (ThermoFischer Scientific, Waltham,
MA USA). The purified RNA was used to generate
cDNA using QuantiTect® Reverse Transcription Kit,
which includes an enzymatic removal of all genomic
DNA (Qiagen, Hilden, Germany). Real-time quantitative
PCR was performed in an Applied Biosystems Quant
Studio™ 7 Flex station (Life Technologies™, Applied Bio-
systems, Foster City, CA, United States). The PCR
primers and FAM-conjugated TaqMan® Gene Expression
Assays probes (Additional file 1: Table S2) were from
LifeTechnologies (Applied Biosystems, Foster City, CA,
United States). The real-time PCR was carried out with
TaqMan® Gene Expression Master Mix (Applied Biosys-
tems, Foster City, CA, United States), which contained
AmpliTaq® Gold DNA Polymerase, AmpErase, UNG,
dNTPs with dUTP, and optimized buffer components.
The thermal cycle conditions were: part A: 50 °C for
2 min to activate the polymerase, part B: 95 °C for
10 min, part C: 95 °C for 15 s for denaturation, and part
D: 60 °C for 1 min for annealing and extension, repeat-
ing part C and D for 45 cycles. We assessed the degree
and specificity of the knockdown of targeted genes;
DNMT1, DNMT3a and DNMT3b using real time quan-
titative PCR (Figs. 2 and 3). Evaluation of an actual func-
tional effect of the knockdown was performed by
measuring if the gene expression of positive control
genes NNAT and S100A10 were upregulated. The two
genes NNAT and S100A10 have previously been reported
to be upregulated upon knockdown of DNMT1 in a
neuronal cell line [59]. For details, see Additional file 1:
Figure S2. MHC-I gene expression was evaluated using
probes against HLA-A, HLA-B and HLA-C in human
SK-N-AS neuroblastoma cell line, and for mouse cells
using probes against β2-microglobulin (β2M), H2-D1,
H2-K1 and a probe detecting H2-D1 and H2-L (H2-D1/
L) as it is not possible to choose TaqMan probes specif-
ically for H2-L. Endogenous expression of ACTB and
GAPDH was measured and used to calculate relative ex-
pression level changes between samples. The signal ob-
tained from HLA-C in SK-N-AS cells, and from H2-K1
in CGNs was undetectable (Ct (HLA-C) > 35, Ct
(H2-K1) > 40), and was not further analyzed.
Immunofluorescence
CGNs were seeded on Nunc™ LabTek™ chamber slides
(ThermoFischer Scientific, Waltham, MA, USA), coated
with poly-D-lysine (Sigma-Aldrich, St. Louis, MO, USA).
Cells were either left untreated, or treated with 0.005 ng/μl
IFNγ, or transfected with (A) non-targeting siRNA, (B)
SMARTpool against DNMT1 or (C) mix of SMARTpool
against DNMT1 and Cy3-labelled siRNA against DNMT1,
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in NBM-A media as described above, and after 72 h of in-
cubation fixated in 4% paraformaldehyde (Electron Micros-
copy Sciences, Hatfield, PA, United States). Cells were
incubated 20 min at room temperature in blocking buffer
(PBS containing 2% BSA (Sigma-Aldrich, St. Louis, MO,
USA), 0.3% TritonX-100 (AppliChem, Darmstadt,
Germany), and 5% Normal Goat Serum (Dako, Glostrup,
Denmark)). Primary antibodies diluted in blocking buffer
were added after blocking, and incubated overnight at room
temperature. Primary antibodies were; rat monoclonal
IgG2a anti-mouse MHC class I antibody (1:200, clone
ErHr52, BMA Biomedicals, Augst, Switzerland), mouse
monoclonal IgG1 anti-β-III-tubulin antibody (1:50, clone
TUJ-1, Santa Cruz, Texas, USA), and rabbit polyclonal
anti-DNMT1 antibody (NB100–264, Novus Biologicals,
CO, USA). After three washing steps in PBS,
fluorophore-conjugated secondary antibodies diluted in
blocking buffer were added, and incubated for 1 h at room
temperature. Secondary antibodies were; Alexa Fluor® 647
goat anti-mouse (1:2000), Alexa Fluor® 555 goat anti-rat (1:
2000), Alexa Fluor® 488 goat anti-rat (1: 2000) and Alexa
Fluor® 488 goat anti-rabbit (1:1000) (all Life Technologies,
OR, USA). 4′,6-Diamidino-2-Phenylindole, Dilactate
(DAPI) (Life Technologies, OR, USA) diluted 1:30.000 in
PBS was added to the cells immediately upon incubation
with secondary antibody, and incubated 8 min at room
temperature. Following three washing steps in PBS, and one
quick rinse in milliQ water, the slides were mounted with
ProLong® Antifade Gold mounting media (Life Technolo-
gies, OR, USA). Immunofluorescence images were taken
with a Zeiss LSM510 confocal scanning microscope, and
analyzed using the Carl Zeiss imaging software Zen Black.
Flow cytometry
CGNs were at day 5 in vitro (DIV5) left untreated, trans-
fected with non-targeting siRNA or with DNMT1 SMART-
pool, or treated with 0.005 ng/μL IFNγ. At DIV8 cells were
harvested by brief trypsinization (2 min, 37 °C) in NBM-A
containing BSA, transferred to 5 ml Falcon tubes for anti-
body staining, and pelleted at 400 RPM, 5 min, 4 °C. Stain-
ing was performed as follows with washes in in 3 ml PBS
(Biowest, Nuaillé, France) between each step. First, cells
were stained for live/dead cells for 30 min at 4 °C using the
Fixable Viability Dye eFluor 506 (eBioscience, Aarhus,
Denmark) diluted in PBS. Blocking of unspecific signal was
done by incubation for 20 min on ice in 10% FCS (Merck
Millipore, Berlin, Germany) diluted in PBS. Staining was
performed for 20 min on ice with PE-conjugated rat IgG2a,κ
anti-mouse MHC-I antibody (clone M1/42, 125,505, BioLe-
gend, Copenhagen, Denmark) or PE-conjugated rat IgG2a,κ
isotype control (clone RTK2758, 400,507, BioLegend,
Copenhagen, Denmark), both diluted to 1 μg/ml PBS con-
taining 2% FCS. If needed, cells were fixated in PBS contain-
ing 2% paraformaldehyde (Electron Microscopy Sciences,
Hatfield, PA, United States) for 15 min at room temperature
on a shaker and permeabilized in PBS containing 0.7%
Tween20 (Bio-Rad, CA, USA) for 15 min at room
temperature on a shaker. Intracellular staining was per-
formed over 30 min at room temperature on a shaker with
Alexa Fluor 647-conjugated mouse IgG2a,κ
anti-β-III-tubulin antibody (clone AA10, 657,405, BioLe-
gend, Copenhagen, Denmark) or Alexa Fluor
647-conjugated mouse IgG2a,κ isotype control (clone
MOPC-173, 400,239, BioLegend, Copenhagen, Denmark),
both diluted to 0.5 μg/ml in PBS containing 0.5% Tween20,
1% BSA (Sigma-Aldrich, St. Louis, MO, USA) and 10%
Donkey Normal Serum (DAKO, Glostrup, Denmark). Fi-
nally, cells were resuspended in either PBS containing 2%
FCS (extracellular staining only, cells not fixated) or in PBS
(intracellular staining, cells fixated) and run on a FACSVerse
flow cytometer (BD Biosciences, NJ, USA) equipped with
FACSuite software for data analysis.
Statistics
The expression of the targeted gene was calculated using
the ΔΔCt method, relative to expression levels of the
housekeeping genes ACTB and GAPDH. Data are pre-
sented as mean fold change with upper and lower inter-
vals calculated as fold change +/− standard error of the
mean (S.E.M.). Statistical significance was tested using
One-Way or Two-Way ANOVA based on the ΔΔCt
values with a Dunnett’s multiple comparison test. The p
values reported are corrected for multiple comparisons.
For testing the effect of treatments, a One-Way ANOVA
with a Dunnett’s multiple comparison test against un-
treated or non-targeting siRNA was used. For testing
synergy between two treatments, a Two-Way ANOVA
with a Dunnett’s multiple comparison test against the
combined treatment, was used.
Additional file
Additional file 1: Figure S1. Transfection efficiency of Cy3-labelled
siRNA in CGNs. CGNs were transfected with Cy3-labelled non-targeting
siRNA as described in Materials and Methods. After 72 h incubation the
cells were fixated and mounted using mounting media containing DAPI.
Epifluorescence images were obtained for DAPI, Cy3-siRNA and overlay.
Arrows with thick arrowhead, transfected cell; thin arrowhead, non-
transfected cell. Figure S2. Generation of a functional positive control of
DNMT1 knockdown. (A) Gene expression of NNAT, CD24A, ICAM1,
RUNX1, and S100A10 [46] in CGNs upon knockdown of DNMT1 relative
to untreated cells. Bonferroni-corrected one-sample t-test: * p1.5 for
NNAT and S100A10 relative to treatment with non-targeting siRNA. (C)
Positive control values for three successful and four unsuccessful experi-
ments (mean ± SD). Table S1. siRNAs from DharmaconTM used in the
study. Table S2. Taqman probes used in the study. (DOCX 930 kb)
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